A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood
Single-rising dose (SRD) part:
The main objectives of the SRD part of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 3009947 in healthy participants following oral administration of single rising doses.
Bioavailability (BA) part:
The main objective of the BA part is to investigate the relative bioavailability of two different BI 3009947 formulations (Formulation A and B) and to assess the influence of food on the relative bioavailability of Formulation A or B.
Protocol Amendment History
6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-11-18; most recent amendment 2026-03-27.
Status change: Completed → Terminated2026-03-27
Status change: Recruiting → Completed2026-03-24
Status change: Not Yet Recruiting → Recruiting2025-11-27